Q-omics provides the consensus-scored MIR629 profile across patient tissues and cancer cell-line models. MIR629 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR629 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, MIR629 RNA expression shows 5,896 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, HNSC, and STAD as cancer lineages where MIR629 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR629 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR629 survival associations across molecular data types. MIR629 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR629 RNA expression–survival associations across cancer types. High MIR629 expression shows unfavorable associations in LIHC, BLCA, READ and HNSC, but favorable associations in SKCM and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR629 RNA expression.
This table summarizes MIR629 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR629. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR629 shows higher tumor expression in HNSC. The HNSC box plot shows higher MIR629 RNA expression in tumor versus normal tissue (log2 FC = +0.348, t-test p = .002).
This table shows molecular features associated with MIR629 in patient tissues and cancer cell lines. In patient samples, MIR629 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
